{"status":"success","data":{"title":"Post-Exposure Prophylaxis, non-occupational contact","slug":"post-exposure-prophylaxis","tags":null,"collection":["Infectious Disease"],"content":"<h1 id=\"post-exposure-prophylaxis-pep-non-occupational-contact\">Post-Exposure Prophylaxis (PEP): Non-Occupational Contact</h1>\n<p><strong>National Clinicians’ Post-Exposure Prophylaxis Hotline of the National HIV/AIDS Clinicians’ Consultation Center</strong></p>\n<ul>\n<li><strong>Phone:</strong> <a href=\"tel:8884484911%20\">1-888-448-4911</a> (24 hrs/day)</li>\n<li>To consult on occupational AND non-occupational exposure to HIV</li>\n</ul>\n<h2 id=\"baseline-testing-of-exposed-patient\">Baseline Testing of Exposed Patient</h2>\n<ul>\n<li>HIV</li>\n<li>Hepatitis B (specifically HBsAb for immunity) </li>\n<li>Hepatitis C antibody </li>\n<li>Gonorrhea</li>\n<li>Chlamydia </li>\n<li>Syphilis</li>\n<li>CBC</li>\n<li>Creatinine</li>\n<li>LFT</li>\n<li>Pregnancy, if appropriate </li>\n</ul>\n<h2 id=\"risk-of-hiv\">Risk of HIV</h2>\n<ul>\n<li>Receptive anal intercourse: 1-30% risk</li>\n<li>Insertive anal or receptive vaginal intercourse: 0.1-10% risk</li>\n<li>Oral intercourse: “very low risk” but not zero risk</li>\n<li>Needle sharing with injection drug use: 0.67% per needle-sharing contact </li>\n</ul>\n<h2 id=\"high-risk-source-patient\">High-Risk Source Patient</h2>\n<ul>\n<li>Known HIV+ source patient </li>\n<li>High-risk populations</li>\n<li>Men who have sex with men+/-women</li>\n<li>Commercial sex workers</li>\n<li>Injection drug users</li>\n<li>History of incarceration</li>\n<li>From a country with HIV seroprevalence ≥ 1%</li>\n<li>Persons with sexual partner in this high-risk population group </li>\n</ul>\n<h2 id=\"if-decide-to-give-pep-for-possible-hiv-exposure\">If Decide to Give PEP for Possible HIV Exposure</h2>\n<ul>\n<li><strong>Timing:</strong> The sooner the treatment, the better. Starting treatment ≤ 48 hours after exposure is best. Still eligible if present ≤ 72 hours per CDC.</li>\n<li><strong>Effectiveness:</strong> PEP is associated with 81% decrease in HIV transmission.</li>\n<li><strong>Duration of treatment</strong> = 28 days</li>\n</ul>\n<p><strong>TREATMENT OPTIONS:</strong></p>\n<p>Option #1: <strong>Combivir</strong> (300 mg <span class=\"drug\">zidovudine</span>-150 mg <span class=\"drug\">lamivudine</span>)- 1 tab po BID</p>\n<ul>\n<li>Side Effects:</li>\n<li>Nausea</li>\n<li>Anemia</li>\n<li>Hepatotoxic</li>\n<li>Neutropenia</li>\n<li>Asthenia</li>\n</ul>\n<p>Option #2: <strong>Truvada</strong> (300 mg <span class=\"drug\">tenofovir</span>-200 mg <span class=\"drug\">emtricitabine</span>) – 1 tab po Qday (Side effects: Nephrotoxic)\nFor very high-risk exposure: Can add to Option #1 or #2:</p>\n<ul>\n<li><strong>Kaletra (<span class=\"drug\">ritonavir</span>-<span class=\"drug\">lopinavir</span>)</strong> (Side effects: Hepatotoxic, diarrhea), or</li>\n<li><p><strong><span class=\"drug\">Ritonavir</span></strong> plus <strong><span class=\"drug\">Atazanavir</span></strong> </p>\n<ul>\n<li>Side Effects:</li>\n<li>Hepatotoxic</li>\n<li>jaundice</li>\n<li>renal stones</li>\n</ul>\n</li>\n<li><p><strong><span class=\"drug\">Ritonavir</span></strong> plus <strong><span class=\"drug\">Darunavir</span></strong> (Side effects: Hepatotoxic, diarrhea)</p>\n</li>\n</ul>\n<p><strong>Followup HIV and syphilis test at 4-6 weeks, 3 months, 6 months post-exposure</strong></p>\n<h2 id=\"additional-treatment\">Additional Treatment</h2>\n<p><a href=\"http://www.cdc.gov/std/treatment/2010/sexual-assault.htm\">CDC Sexual Assault and STD website</a></p>\n<ul>\n<li><strong><span class=\"drug\">Ceftriaxone</span></strong> 250 mg IM x 1 (for Gonorrhea) - or can give IV</li>\n<li><strong><span class=\"drug\">Azithromycin</span></strong> 1 g po x 1 (for Chlamydia)</li>\n<li><strong><span class=\"drug\">Metronidazole</span></strong> 2 g po x 1 (for trichomonas)</li>\n<li>Consider <strong>emergency contraception</strong> for women</li>\n<li><strong>Hep B vaccination</strong>, if not fully vaccinated – need to finish series at 1-2 &amp; 4-6 mo </li>\n</ul>\n<h2 id=\"references\">References</h2>\n<ul>\n<li><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/?term=19864675\">Landovitz RJ, Currier JS. Clinical practice. Postexposure prophylaxis for HIV infection. N Engl J Med. 2009 Oct 29;361(18):1768-75.</a></li>\n</ul>\n"}}